Our study has identified, in addition to systemic levels of testosterone, tumor-specific AR and its fucosylation signaling effectors (FUT4, fucosylated-L1CAM, and AJs), as potential risk factors for disease progression and as promising prognostic biomarkers. The gene discussed is AR; the disease is neoplasm.